DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20172126

Correlation of HBsAg quantitation by ELISA with serum hepatitis B virus DNA quantitative PCR in chronic hepatitis B patients

Sandesh Kolassery

Abstract


Background: Serum HBV DNA is a useful and reliable marker to diagnose and monitor CHB on treatment. The limitation of HBV DNA is that it is expensive and that the assays lack uniformity and standardization. Hence there is a need for more economical and reliable marker. HBsAg quantitation is one such surrogate serological marker. The objective of the current study is to compare and correlate the serum hepatitis B DNA quantitative PCR with HBsAg quantitation.

Methods: Patients with CHB attending to the outpatient clinic of Gastroenterology department were enrolled in the study. Patients with undetectable HBV DNA levels and those co-infected with HCV or HIV were excluded from the study. All patients were tested for serological markers like HBsAg (rapid), HBeAg, anti HBe and HBV DNA-PCR. HBsAg quantification was done using conventional ELISA immunoassay. HBV-DNA and qHBsAg levels were expressed in log10IU/ml. Pearson correlation was used to estimate correlation between HBV DNA and HBsAg quantitation. Statistical analysis was done using SPSS and P value of <0.05 was considered significant.

Results: A total of 38 patients were enrolled in the study. 23.62% were females and mean age of patients in the entire study group was 35.72 years. The mean ALT level was 103.80U/L. 26.32% (n = 10) were HBeAg positive. Mean HBV DNA and qHBsAg levels for the entire cohort were 5.81 log10IU/ml and 5.83 log10IU/ml respectively with a correlation coefficient of 0.318 (P = 0.130). For HBeAg positive patients the mean HBV DNA and qHBsAg levels were 7.90 log10IU/ml and 5.91 log10IU/ml respectively with a correlation coefficient of 0.722 (P = 0.043). HBV DNA levels were significantly higher in HBeAg positive patients compared with HBeAg negative patients (7.9 versus 4.01; P = 0.002). qHBsAg levels were also marginally high in HBeAg positive patients (5.91 versus 5.8; P = 0.136). Neither HBV DNA levels nor qHBsAg levels correlated with serum ALT levels.

Conclusions: There is a significant correlation between quantitative HBsAg levels and HBV-DNA levels in HBeAg positive patients with chronic hepatitis B but not in HBeAg negative patients. HBV-DNA levels are significantly higher in HBeAg positive patients.


Keywords


Chronic hepatitis B, HBsAg quantitation, Hepatitis B DNA PCR, Quantitative HBsAg

Full Text:

PDF

References


Kowdley KV, Wang CC, Welch S, Roberts H, Brosgart CL. Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatol. 2012;56:422-33.

Bosch FX, Ribes J, Cléries R, Díaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005;9:191-211.

Gust ID. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gut. 1996;38(Suppl 2):S18-23.

World Health Organization. Hepatitis B. World Health Organization Fact Sheet No 204, 2014. Available at http://www.who.int/mediacentre /fact sheets/fs204/en/.

Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97-107.

Lok AS. Chronic hepatitis B. N Engl J Med. 2002;346:1682-3.

Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol. 2005;34:1329-39.

Gish RG, Locarnini SA. Chronic hepatitis B: Current testing strategies. Clin Gastroenterol Hepatol. 2006;4:666-76.

Andersson KL, Chung RT. Monitoring during and after antiviral therapy for hepatitis B. Hepatol. 2009;49:S166-73.

Deguchi M, Yamashita N, Kagita M, Asari S, Iwatani Y, Tsuchida T, et al. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods. 2004;115:217-22.

Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatol. 2009;49:1151-7.

Wursthorn K, Jung M, Riva A, Goodman ZD, Lopez P, Bao W, et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B antigen-positive patients. Hepatol. 2010;52:1611-20.

Chan HL, Wong VW, Tse AM, Tse C, Chim AM, Chan H, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol. 2007;5:1462-8.

Kuhns MC, Kleinman SH, McNamara AL, Rawal B, Glynn S, Busch MP. Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: Implications for future HBV screening policy. Transfus. 2004;44:1332-9.

Kohmoto M, Enomoto M, Tamori A, Habu D, Takeda T, Kawada N, et al. Quantitative detection of hepatitis B surface antigen by chemiluminiscent microparticle immunoassay during lamivudine treatment. J Med Virol. 2005;75:235-9.

Ozaras R, Tabak F, Tahan V, Ozturk R, Akin H, Mert A, et al. Correlation of quantitative assay of HBsAg and HBV DNA levels during chronic HBV treatment. Dig Dis Sci. 2008;53:2995-8.

Thakur V, Guptan RC, Kazim SN, Malhotra V, Sarin SK. Profile, spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinent. J Gastroenterol Hepatol. 2002;17:165-70.

Andersson KL, Chung RT. Monitoring during and after antiviral therapy for hepatitis B. Hepatol. 2009;49:S166-73.

Ozdil B, Cosar AM, Akkiz H, Sandikci MU, Kece C. Negative correlation between viral load and HBsAg levels in chronic HBV-infected patients. Arch Virol. 2009;154:1451-5.

Kohmoto M, Enomoto M, Tamori A, Habu D, Takeda T, Kawada N, et al. Quantitative detection of hepatitis B surface antigen by chemiluminiscent microparticle immunoassay during lamivudine treatment. J Med Virol. 2005;75:235-9.

Ozaras R, Tabak F, Tahan V, Ozturk R, Akin H, Mert A, et al. Correlation of quantitative assay of HBsAg and HBV DNA levels during chronic HBV treatment. Dig Dis Sci. 2008;53:2995-8.

Sonneveld MJ, Zoutendijk R, Janssen HL. Hepatitis B surface antigen monitoring and management of chronic hepatitis B. J Viral Hepat. 2011;18:449-57.

Kuhns MC, Kleinman SH, McNamara AL, Rawal B, Glynn S, Busch MP. Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: Implications for future HBV screening policy. Transfus. 2004;44:1332-9.